KIMBERLY HOGAN: Open Payments
NPI 1912310509 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$448 in 23 payments from 12 companies in 2025. Trend: 2023 $1,009 · 2024 $756 · 2025 $448
Food & beverage: $448
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $87 |
| Lilly USA, LLC | 3 | $80 |
| GlaxoSmithKline, LLC. | 4 | $71 |
| Merck Sharp & Dohme LLC | 2 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| ABBVIE INC. | 1 | $17 |
Products named: TRELEGY ELLIPTA, JARDIANCE, GARDASIL 9, XIFAXAN, Wegovy, Ozempic, KISUNLA, GEMTESA.
Industry payments across FL — which companies pay providers there.
